Latest Advances in Lung Cancer Research

A study shows promising results of a drug that helps the immune system fight cancer before surgery in patients with operable tumors.

An interview with Dr. Gregory Masters discussing the latest guidelines treating non-small cell lung cancer (NSCLC) with gene mutations.

Patients with non-small cell lung cancer with METex14 tumor have improved survival outcomes following savolitinib treatment.

Lorlatinib approved for ALK-Positive NSCLC. The FDA expands approval of Lorlatinib for frontline treatment of ALK+ lung cancer patients.

Research shows using both immunotherapy and chemotherapy for treatment doubles survival among those diagnosed with lung cancer.

KRAS mutation, previously seen as “undruggable” sees promise for new therapies through improbable targets for lung cancer.

Patients with pretreated SCLC have improved outcomes. Apatinib combined with chemotherapy in patients with prior treatments indicate good efficacy/safety.

IASLC discusses lung cancer care and research disparities among socioeconomic, ethnic, racial, and gender-related groups.

How biomarkers impact treatment decisions. Biomarkers indicate that a patient’s immune system knows that the tumor is there.

A sizable body of research has long shown racial disparities in treatment and survival between Black and White patients with lung cancer.

Amgen has filed its trailblazer KRAS inhibiting drug treatment with the FDA for a group of lung cancer patients with an aggressive form of the disease.